In this systematic review and network meta‐analysis, we updated data and comprehensively performed the comparison of multiple first‐line treatments, including PD‐(L)1, CTLA‐4, anti‐angiogenesis, CDK inhibitor, CXCR inhibitor, PARP inhibitor, chemotherapy, EP, and their combination regimens for treatment‐naïve ES‐SCLC. The gene discussed is CD274; the disease is small cell lung carcinoma.